Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
• Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
• Patients of both sexes aged ≥ 18 years at enrollment
• Signature of informed consent
Locations
Other Locations
Italy
IRCCS Azienda Ospedaliero - Universitaria di Bologna
RECRUITING
Bologna
Contact Information
Primary
Pier Luigi Zinzani, MD
pierluigi.zinzani@unibo.it
+390512144042
Backup
Cinzia Pellegrini, MD
cinzia.pellegrini@aosp.bo.it
+390512103680
Time Frame
Start Date: 2022-11-03
Estimated Completion Date: 2025-09-30
Participants
Target number of participants: 200
Treatments
Experimental: hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed
in vitro human tissue testing of peripheral blood in hodgkin lymphoma patients in complete remission for at least two years after first-line therapy with stage II b, III or IV
Related Therapeutic Areas
Sponsors
Leads: IRCCS Azienda Ospedaliero-Universitaria di Bologna